390 related articles for article (PubMed ID: 28930171)
1. Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.
Nørgaard M; Haldrup C; Storebjerg TM; Vestergaard EM; Wild PJ; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28930171
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.
Terry S; Nicolaiew N; Basset V; Semprez F; Soyeux P; Maillé P; Vacherot F; Ploussard G; Londoño-Vallejo A; de la Taille A; Allory Y
Cancer; 2015 May; 121(9):1422-30. PubMed ID: 25639219
[TBL] [Abstract][Full Text] [Related]
4. Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels.
Haldrup C; Lynnerup AS; Storebjerg TM; Vang S; Wild P; Visakorpi T; Arsov C; Schulz WA; Lindberg J; Grönberg H; Egevad L; Borre M; Ørntoft TF; Høyer S; Sørensen KD
Mol Oncol; 2016 Jun; 10(6):825-37. PubMed ID: 26905753
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypomethylation and upregulation of trefoil factors in prostate cancer.
Vestergaard EM; Nexø E; Tørring N; Borre M; Ørntoft TF; Sørensen KD
Int J Cancer; 2010 Oct; 127(8):1857-65. PubMed ID: 20112343
[TBL] [Abstract][Full Text] [Related]
6. Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies.
Haldrup C; Pedersen AL; Øgaard N; Strand SH; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Mol Oncol; 2018 Apr; 12(4):545-560. PubMed ID: 29465788
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
[TBL] [Abstract][Full Text] [Related]
8. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Strand SH; Switnicki M; Moller M; Haldrup C; Storebjerg TM; Hedegaard J; Nordentoft I; Hoyer S; Borre M; Pedersen JS; Wild PJ; Park JY; Orntoft TF; Sorensen KD
Oncotarget; 2017 Jan; 8(4):5774-5788. PubMed ID: 28052017
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation signatures for prediction of biochemical recurrence after radical prostatectomy of clinically localized prostate cancer.
Haldrup C; Mundbjerg K; Vestergaard EM; Lamy P; Wild P; Schulz WA; Arsov C; Visakorpi T; Borre M; Høyer S; Orntoft TF; Sørensen KD
J Clin Oncol; 2013 Sep; 31(26):3250-8. PubMed ID: 23918943
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
Storebjerg TM; Strand SH; Høyer S; Lynnerup AS; Borre M; Ørntoft TF; Sørensen KD
Clin Epigenetics; 2018 Aug; 10(1):105. PubMed ID: 30086793
[TBL] [Abstract][Full Text] [Related]
11. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
12. SLCO4C1 promoter methylation is a potential biomarker for prognosis associated with biochemical recurrence-free survival after radical prostatectomy.
Li X; Zhang W; Song J; Zhang X; Ran L; He Y
Clin Epigenetics; 2019 Jul; 11(1):99. PubMed ID: 31288850
[TBL] [Abstract][Full Text] [Related]
13. PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies.
Uhl B; Gevensleben H; Tolkach Y; Sailer V; Majores M; Jung M; Meller S; Stein J; Ellinger J; Dietrich D; Kristiansen G
J Mol Diagn; 2017 Jan; 19(1):107-114. PubMed ID: 27939865
[TBL] [Abstract][Full Text] [Related]
14. CXCL12 promoter methylation and PD-L1 expression as prognostic biomarkers in prostate cancer patients.
Goltz D; Holmes EE; Gevensleben H; Sailer V; Dietrich J; Jung M; Röhler M; Meller S; Ellinger J; Kristiansen G; Dietrich D
Oncotarget; 2016 Aug; 7(33):53309-53320. PubMed ID: 27462860
[TBL] [Abstract][Full Text] [Related]
15. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy.
Gevensleben H; Holmes EE; Goltz D; Dietrich J; Sailer V; Ellinger J; Dietrich D; Kristiansen G
Oncotarget; 2016 Nov; 7(48):79943-79955. PubMed ID: 27835597
[TBL] [Abstract][Full Text] [Related]
17. High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer.
Strand SH; Hoyer S; Lynnerup AS; Haldrup C; Storebjerg TM; Borre M; Orntoft TF; Sorensen KD
Clin Epigenetics; 2015; 7():111. PubMed ID: 26478752
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and prognosis potential of four gene promoter hypermethylation in prostate cancer.
Li Y; Meng L; Shi T; Ren J; Deng Q
Cell Biol Int; 2021 Jan; 45(1):117-126. PubMed ID: 32991011
[TBL] [Abstract][Full Text] [Related]
19. CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S; Zipfel L; Gevensleben H; Dietrich J; Ellinger J; Majores M; Stein J; Sailer V; Jung M; Kristiansen G; Dietrich D
Epigenetics; 2016 Dec; 11(12):871-880. PubMed ID: 27689475
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]